Beta

Geron corporationGERN.US Overview

US StockHealthcare
(No presentation for GERN)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

GERN AI Insights

GERN Overall Performance

GERN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GERN Recent Performance

-1.31%

Geron corporation

-1.10%

Avg of Sector

-0.49%

S&P500

GERN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check GERN's Trend

GERN Key Information

GERN Valuation Metrics

GERN Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Price of GERN

GERN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GERN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5.23
PB Ratio
4.26
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
97.42%
Net Margin
-45.41%
Revenue Growth (YoY)
138.83%
Profit Growth (YoY)
136.52%
3-Year Revenue Growth
675.38%
3-Year Profit Growth
668.28%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5.23
PB Ratio
4.26
Price-to-FCF
-
Gross Margin
97.42%
Net Margin
-45.41%
Revenue Growth (YoY)
138.83%
Profit Growth (YoY)
136.52%
3-Year Revenue Growth
675.38%
3-Year Profit Growth
668.28%
  • When is GERN's latest earnings report released?

    The most recent financial report for Geron corporation (GERN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GERN's short-term business performance and financial health. For the latest updates on GERN's earnings releases, visit this page regularly.

  • What is the operating profit of GERN?

    According to the latest financial report, Geron corporation (GERN) reported an Operating Profit of -25.54M with an Operating Margin of -53.19% this period, representing a decline of 27.38% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is GERN's revenue growth?

    In the latest financial report, Geron corporation (GERN) announced revenue of 48.02M, with a Year-Over-Year growth rate of 1.01%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does GERN have?

    As of the end of the reporting period, Geron corporation (GERN) had total debt of 251.57M, with a debt ratio of 0.44. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does GERN have?

    At the end of the period, Geron corporation (GERN) held Total Cash and Cash Equivalents of 79.44M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does GERN go with three margins increasing?

    In the latest report, Geron corporation (GERN) did not achieve the “three margins increasing” benchmark, with a gross margin of 97.3%%, operating margin of -53.19%%, and net margin of -60.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess GERN's profit trajectory and future growth potential.

  • Is GERN's EPS continuing to grow?

    According to the past four quarterly reports, Geron corporation (GERN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GERN?

    Geron corporation (GERN)'s Free Cash Flow (FCF) for the period is -22.07M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 49.62% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.